Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 3/20 | 1.00 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.65 |
| ▸ | NQO2 | P16083 | 4/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 2/20 | 0.62 |
| ▸ | TTR | P02766 | 2/20 | 0.62 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.62 |
| ▸ | BCR | P11274 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.62 |
| ▸ | TUBB | P07437 | 1/20 | 0.62 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.62 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4735253 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL4733440 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL3395077 | 0.93 | PTGS2 (0.86) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL12830656 | 0.91 | PTGS2 (0.83) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL1005735 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1TLR9CYP19A1NFE2L2 | |
| SCHEMBL1005734 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1TLR9CYP19A1NFE2L2 | |
| SCHEMBL1405454 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL1405456 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1TLR9CYP19A1NQO2 | |
| SCHEMBL4255411 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1TLR9CYP19A1NFE2L2 | |
| SCHEMBL4255409 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1TLR9CYP19A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | claimed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | claimed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | claimed |
| JP-7267905-A | — | — | None | — | — | JP | disclosed |
| CN-119285447-A | Preparation method of pterostilbene | 中国药科大学 | 2025-01-10 | — | — | CN | disclosed |
| CN-108514539-B | Antiseptic composition for cosmetics based on mild effect and preparation method of cosmetics | 广州市腾宇化妆品有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-8426369-B2 | Prevention and treatment of colon cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-07-12 | — | — | US | disclosed |
| WO-2010046926-A2 | NOVEL STILBENE ANALOGS | APTUIT LAURUS PVT LTD (IN) | 2010-04-29 | — | — | WO | disclosed |
| WO-2008070872-A1 | PREVENTION AND TREATMENT OF COLON CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2008-06-12 | — | — | WO | disclosed |
| JP-H07267905-A | NITRO COMPOUND AND AMINO COMPOUND AND THEIR PRODUCTION | RICOH CO LTD | 1995-10-17 | — | — | JP | disclosed |
| US-4921871-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4874758-A | LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| US-4868200-A | LEUKOTRIENES, LIPOXYGENASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868195-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868205-A | ANTIALLERGENS, ANTIINFLAMMATORY, CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4868199-A | ENZYME INHIBITORS, ANTIALLERGEN, ASTHMA, CARDIOVASCULAR, ANTIINFLAMMATORY | WARNER-LAMBERT COMPANY (US) | 1989-09-19 | — | — | US | disclosed |
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
| EP-0221346-A1 | (N-substituted-2-hydroxy) benzamides and N-substituted-2-hydroxy-alpha-oxo-benzeneacetamides and pharmaceutical compositions thereof having activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178704-A1 | PREVENTION AND TREATMENT OF COLON CANCER | APC, SI, NFKBIA | PTGS2 28/4885PTGS1 13/4885TLR9 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.